Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis (Q34189582)

31 July 2017

4 references

13 March 2019

24 March 2019

20 August 2019

23 November 2020

Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis (English)

1 reference

postmenopausal osteoporosis

31 July 2017

0 references

4 references

13 March 2019

24 March 2019

20 August 2019

23 November 2020

physiological phenomenon

1 reference

20 August 2019

adverse drug reaction

1 reference

23 November 2020

0 references

Gérard Bréart

4

0 references

Cyrus Cooper

object named as

Cyrus Cooper

series ordinal

9

0 references

Jean-Yves Reginster

series ordinal

2

object named as

Jean-Yves Reginster

1 reference

31 July 2017

8

John A Kanis

1 reference

31 July 2017

7

Jean-Marc Kaufman

1 reference

31 July 2017

3

Steven Boonen

1 reference

31 July 2017

6

Dieter Felsenberg

1 reference

31 July 2017

5

Adolfo Diez-Perez

1 reference

31 July 2017

1

René Rizzoli

1 reference

31 July 2017

language of work or name

English

0 references

publication date

3 June 2011

1 reference

Calcified Tissue International

31 July 2017

1 August 2011

4 references

13 March 2019

24 March 2019

20 August 2019

23 November 2020

5 references

31 July 2017

13 March 2019

24 March 2019

20 August 2019

23 November 2020

89

1 reference

31 July 2017

91-104

1 reference

31 July 2017

2

1 reference

https://scigraph.springernature.com/pub.10.1007/s00223-011-9499-8

31 July 2017

0 references

cites work

Bisphosphonates for post-menopausal osteoporosis: are they all the same?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Exposure to oral bisphosphonates and risk of esophageal cancer.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Do RANKL inhibitors (denosumab) affect inflammation and immunity?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Adverse effects of bisphosphonates

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Lasofoxifene in postmenopausal women with osteoporosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Long-term use of bisphosphonates in osteoporosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Atrial fibrillation and bisphosphonate therapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Bisphosphonate-associated adverse events.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Adverse effects of bisphosphonates: implications for osteoporosis management

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

The epidemiology of osteonecrosis: findings from the GPRD and THIN databases in the UK

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Osteoporosis treatments and adverse events

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws--2009 update

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Bisphosphonates and atrial fibrillation: systematic review and meta-analysis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Safety of bisphosphonates in the treatment of osteoporosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Teriparatide: a review of its use in osteoporosis.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Effect of raloxifene on stroke and venous thromboembolism according to subgroups in postmenopausal women at increased risk of coronary heart disease

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Pharmacovigilance: methods, recent developments and future perspectives

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Risks and benefits of bisphosphonates

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Low-energy femoral shaft fractures associated with alendronate use.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Use of alendronate and risk of incident atrial fibrillation in women

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

An overview of drug-induced acute kidney injury

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Osteonecrosis of the jaw and bisphosphonate treatment for osteoporosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Incidence of osteonecrosis of the jaw in women with postmenopausal osteoporosis in the health outcomes and reduced incidence with zoledronic acid once yearly pivotal fracture trial.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Safety considerations with bisphosphonates for the treatment of osteoporosis.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Inter-expert agreement of seven criteria in causality assessment of adverse drug reactions

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Therapy insight: the risks and benefits of bisphosphonates for the treatment of tumor-induced bone disease.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Safety assessment of raloxifene over eight years in a clinical trial setting

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Severely suppressed bone turnover: a potential complication of alendronate therapy

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Drug-induced renal failure: update on new medications and unique mechanisms of nephrotoxicity

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Patients' understanding of risk associated with medication use: impact of European Commission guidelines and other risk scales

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Protective effects of estrogen and selective estrogen receptor modulators in the brain

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence?

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Upper gastrointestinal tract safety of risedronate: a pooled analysis of 9 clinical trials

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Adverse drug reactions: definitions, diagnosis, and management

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Raloxifene: a review of its use in postmenopausal osteoporosis

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d'Etude de la Thrombose de Bretagne Occidentale.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Cost-equivalence of different osteoporotic fractures

5 July 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9499-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9499-8

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9499-8

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9499-8

Reports of esophageal cancer with oral bisphosphonate use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9499-8

Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9499-8

Alendronate and atrial fibrillation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9499-8

Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9499-8

Unusual mid-shaft fractures during long-term bisphosphonate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9499-8

Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9499-8

Trabecular bone microarchitecture after alendronate treatment of osteoporotic women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9499-8

Bisphosphonate-associated osteonecrosis of the jaw: a key role of inflammation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9499-8

Renal safety of annual zoledronic acid infusions in osteoporotic postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9499-8

Increased risk of serious infections in women with osteopenia or osteoporosis treated with denosumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9499-8

Osteonecrosis of the jaws induced by anti-RANK ligand therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9499-8

Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9499-8

Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9499-8

Design and methods of the Raloxifene Use for The Heart (RUTH) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9499-8

Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9499-8

Bazedoxifene, a selective estrogen receptor modulator: effects on the endometrium, ovaries, and breast from a randomized controlled trial in osteoporotic postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9499-8

Another selective estrogen-receptor modulator for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9499-8

Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9499-8

Vascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial: incidence, patient characteristics, and effect of raloxifene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9499-8

Effect of raloxifene on cardiovascular adverse events in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9499-8

Effect of raloxifene on prevention of dementia and cognitive impairment in older women: the Multiple Outcomes of Raloxifene Evaluation (MORE) randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9499-8

Intelligent risk communication: can it be improved?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9499-8

Combination teriparatide and raloxifene therapy for postmenopausal osteoporosis: results from a 6-month double-blind placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9499-8

Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9499-8

Fracture risk in patients receiving acid-suppressant medication alone and in combination with bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9499-8

Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9499-8

Intravenous ibandronate injections in postmenopausal women with osteoporosis: One-year results from the dosing intravenous administration study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00223-011-9499-8

Yearly zoledronic acid in postmenopausal osteoporosis

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3135835

Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial

9 December 2018

1 reference

12 December 2020

Incidence and mortality of venous thrombosis: a population-based study

1 reference

12 December 2020

Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention

1 reference

12 December 2020

Provision of information about drug side-effects to patients

1 reference

12 December 2020

Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety

1 reference

12 December 2020

Osteonecrosis of the jaw and bisphosphonates

1 reference

12 December 2020

1 reference

12 December 2020

Osteosarcoma and teriparatide?

1 reference

12 December 2020

Difficulties in assessing adverse drug reactions in clinical trials

1 reference

12 December 2020

10.1007/S00223-011-9499-8

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

0 references

1 reference

31 July 2017

1 reference